|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - CHF | -.--% |
|
-.--% | - |
| 06-16 | PTC Therapeutics Prices $500 Million Notes Offering | MT |
| 06-15 | PTC Therapeutics Plans $500 Million Convertible Notes Offering to Refinance 2026 Notes | MT |
Company Valuation: PTC Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,816 | 2,786 | 2,080 | 3,481 | 6,099 | 6,551 | - | - |
| Change | - | -1.06% | -25.35% | 67.4% | 75.18% | 7.42% | - | - |
| Enterprise Value (EV) 1 | 2,474 | 2,947 | 1,487 | 2,627 | 4,440 | 4,768 | 4,711 | 4,378 |
| Change | - | 19.12% | -49.54% | 76.65% | 69% | 7.38% | -1.19% | -7.06% |
| P/E | -5.36x | -4.9x | -3.29x | -9.54x | 9.76x | 89.1x | 31.6x | 27.8x |
| PBR | 1,952x | -7.89x | -2.55x | -3.19x | -30.1x | -878x | 15.9x | 5.51x |
| PEG | - | -1.01x | -0.44x | 0.2x | -0x | -1x | 0x | 2x |
| Capitalization / Revenue | 5.23x | 3.99x | 2.22x | 4.32x | 3.52x | 5.58x | 4.99x | 4.19x |
| EV / Revenue | 4.59x | 4.22x | 1.59x | 3.26x | 2.57x | 4.06x | 3.59x | 2.8x |
| EV / EBITDA | -7.97x | -9.25x | -7.33x | -11.6x | 4.9x | 15.5x | 10.2x | 5.82x |
| EV / EBIT | -6.61x | -6.59x | -3.38x | -8.68x | 5.12x | 16.5x | 11.4x | 7.67x |
| EV / FCF | -8.85x | -7.58x | -7.96x | -23x | 6.32x | 58.9x | 165x | 26.9x |
| FCF Yield | -11.3% | -13.2% | -12.6% | -4.35% | 15.8% | 1.7% | 0.6% | 3.72% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7.43 | -7.79 | -8.37 | -4.73 | 7.78 | 0.8861 | 2.498 | 2.844 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 538.6 | 698.8 | 937.8 | 806.8 | 1,731 | 1,173 | 1,312 | 1,565 |
| EBITDA 1 | -310.3 | -318.6 | -202.9 | -226.9 | 905.8 | 307.3 | 462.3 | 751.8 |
| EBIT 1 | -374.4 | -447.4 | -439.5 | -302.6 | 866.9 | 288.4 | 414.2 | 571.1 |
| Net income 1 | -523.9 | -559 | -626.6 | -363.3 | 682.6 | 65.46 | 177.9 | 260.1 |
| Net Debt 1 | -341.9 | 161 | -592.5 | -854.3 | -1,659 | -1,784 | -1,840 | -2,173 |
| Reference price 2 | 39.83 | 38.17 | 27.56 | 45.14 | 75.96 | 78.98 | 78.98 | 78.98 |
| Nbr of stocks (in thousands) | 70,698 | 72,991 | 75,463 | 77,125 | 80,288 | 82,949 | - | - |
| Announcement Date | 2/22/22 | 2/21/23 | 2/29/24 | 2/27/25 | 2/19/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.01x | 11.69x | 23.99x | 0.62% | 980B | |
| 24.41x | 5.63x | 15.32x | 2.34% | 550B | |
| 26.86x | 6.49x | 13.28x | 3.17% | 382B | |
| 17.04x | 4.24x | 10.43x | 3.13% | 316B | |
| 21.94x | 4.59x | 13.02x | 1.91% | 272B | |
| 20.28x | 5.27x | 12.78x | 3.05% | 268B | |
| 13x | 4.83x | 9.94x | 3.87% | 199B | |
| 21.95x | 5.91x | 10.33x | 2.99% | 182B | |
| -44.34x | 5.36x | 29.54x | 2.62% | 154B | |
| Average | 14.79x | 6.00x | 15.40x | 2.63% | 366.93B | |
| Weighted average by Cap. | 21.68x | 7.24x | 16.85x | 2.17% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- PTCT Stock
- P91 Stock
- Valuation PTC Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
